Damian Alvarez-Paggi | CEO
Eureka Nanobioengineering

Damian Álvarez Paggi is Co-Founder & CEO of Eureka Nanobioengineering, a Buenos Aires–based biotech innovator. He is a scientist, entrepreneur, professor, and communicator with over 15 years of leadership in academic research, R&D, and biotech ventures. He holds a PhD in Biophysical Chemistry from the University of Buenos Aires (UBA) and specializes in nanobiotechnology, protein engineering, and translational medicine.
His research spans host–pathogen interactions, molecular virology, and the preclinical and clinical evaluation of vaccines and therapeutics against respiratory viruses including RSV and SARS-CoV-2. He leads the development of self-assembling platforms for modular vaccines and immunotherapies.
He has secured competitive public and private funding for Eureka NBE and participated in collaborative projects funded by the NIH, the UK Medical Research Council, and the Bill & Melinda Gates Foundation. His 40 peer-reviewed publications appear in leading journals such as NEJM, PNAS, JACS, Science Translational Medicine, and Chemical Reviews. He holds two European patent applications for modular nanoparticle platforms.
Combining technical depth with strategic vision, Damian translates cutting-edge discoveries into innovative, scalable solutions that address unmet medical needs effectively and improve timely global health readiness.